prolor biotech inc
(PBTH:Consolidated issues listed on NYSE MKT LLC)
prolor biotech inc (PBTH) Snapshot
|
Open
$6.48
|
Previous Close
$6.49
|
|
|
Day High
$6.56
|
Day Low
$6.40
|
|
|
52 Week High
05/20/13 - $6.56
|
52 Week Low
11/27/12 - $4.25
|
|
|
Market Cap
408.2M
|
Average Volume 10 Days
335.2K
|
|
|
EPS TTM
$-0.28
|
Shares Outstanding
63.7M
|
|
|
EX-Date
--
|
P/E TM
--
|
|
|
Dividend
--
|
Dividend Yield
--
|
Related News
prolor biotech inc (PBTH) Related Businessweek News
prolor biotech inc (PBTH) Details
PROLOR Biotech, Inc., a development stage biopharmaceutical company, engages in the development of proprietary versions of already-approved therapeutic proteins. Its technology, Carboxyl Terminal Peptide (CTP) is used to develop new and proprietary versions of existing therapeutic proteins that have longer life spans than therapeutic proteins without CTP. The company’s products under development include human growth hormone, which is used for the long-term treatment of children and adults with growth failure due to inadequate secretion of endogenous growth hormone; and factor IX that is offered to Hemophilia B patients to control blood clotting or coagulation. Its products under development also comprise anti-obesity peptide oxyntomodulin, factor VIIa, interferon ß and erythropoietin, and atherosclerosis and rheumatoid arthritis long-acting therapies. The company was formerly known as Modigene Inc. and changed its name to PROLOR Biotech, Inc. in June 2009. PROLOR Biotech, Inc. is based in Nes-Ziona, Israel.
Last Reported Date: 03/15/13
prolor biotech inc (PBTH) Top Compensated Officers
prolor biotech inc (PBTH) Key Developments
To discuss the acquisition of PROLOR Biotech, Inc. by Opko Health, Inc
PROLOR Biotech, Inc. has retained Jefferies Group Inc. to evaluate strategic alternatives, a person close to the matter said. The person stated that the company will evaluate the economic value of its projects and has not yet decided to sell itself. PROLOR’s shares rose 3.4% to $5.19.
PROLOR Biotech, Inc. announced that it received a notice of allowance from the U.S. Patent and Trademark Office for a new patent application covering the company's proprietary long-acting CTP-enhanced coagulation factors for the treatment of hemophilia: Factor VIIa-CTP, Factor Vll-CTP and Factor IX-CTP. The allowed claims cover both product composition and treatment methods. The new patent allowance is important for PROLOR, as the company move forward with plans to initiate a Phase II clinical study of company's long-acting Factor VIIa-CTP in early 2014. The new patent is expected to issue in the next few months.
| Recently Viewed | |||
| PBTH:US | $6.41 USD | -0.08 |  |
| Company | Last | Change | |
| No competitor information is available for PBTH. | |||
| View Industry Companies | |||
Industry Analysis
PBTH
Industry Average
| Valuation | PBTH | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | -- | Not Meaningful |
| Price/Book | 14.0x |
|
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | -- | Not Meaningful |
Post a JobJobs
- New York, NY |Posted: May 17
- San Francisco, CA | YelpPosted: May 02
- San Francisco, CA | YelpPosted: May 02
- Thornton, CO | IntuitPosted: May 20
Sponsored Financial Commentaries
Sponsored Links
To contact PROLOR BIOTECH INC, please visit www.prolor-biotech.com. Company data is provided by Capital IQ. Please use this form to report any data issues.
Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.
